middle.news
Percheron Therapeutics Launches $2.2M Entitlement Offer to Advance Cancer Drug
10:22am on Monday 16th of March, 2026 AEDT
•
Biotechnology
Read Story
Percheron Therapeutics Launches $2.2M Entitlement Offer to Advance Cancer Drug
10:22am on Monday 16th of March, 2026 AEDT
Key Points
2 for 5 entitlement offer at $0.005 per share with ~20% discount
Free attaching options exercisable at $0.01 over two years
Funds to support HMBD-002 phase II clinical trial and working capital
Offer includes a shortfall facility but is not underwritten
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE